Circio Holding ASA (CRNA) - tidl: Targovax (TRVX) 1

[Tippe]

Hvor mange ganger til vil de potensielt endre på det?

[TekBot]

Atlas Holdings for CIRCIO

Pursuant to Securities Trading Regulation (STR), section 4-1, Atlas Special Opportunities, LLC hereby notifies you that we have crossed the notification requirement threshold in Circio Holding, with ticker CRNA, NO0013033795. Please see below for details on the ownership details resulting from transactions occurring on June 06, 2024. Please let us know if you require any additional information.

Value Date 06/06/2024
…

Vis børsmeldingen

Start of Day Position 1,837,971.00
End of Day Position 1,681,638
Outstanding Shares 9,473,813.00
Ownership Percentage 17.75%

Kilde

[Buffet]

@aborum

Jeg må sige at Erik leverer en stærk dialog på denne præsentation og sender et tydeligt signal om potentialet til selskabet samt arbejdet med potentielle partnere

Denne har vel gått på repeat siden 2016? For TG og Oncos også…

[aborum]

@Buffet

Denne har vel gått på repeat siden 2016?

Jeg vil argumentere for at konteksten er en anden; selskabet er jo bl.a. funderet på en teknologi, hvor man vel oprigtigt kan sige, de er med blandt front runners - det var jo ikke helt tilfældet før.

Men det ændrer ikke på, at præsentationen (efter min mening) var engagerende.

[Buffet]

@aborum

hvor man vel oprigtigt kan sige, de er med blandt front runners - det var jo ikke helt tilfældet før.

TG gikk vel i den kategorien? Oncos ble det vel heller brukt «best in class».

[aborum]

Jeg vil mene man nemt kan argumentere for at circRNA er en væsentligt nyere og langt mere potent opdagelse end peptider og modificerede adeno vira.

Der er stærke signaler i markedet om at alle behandlinger, der p.t. er baseret på lineær RNA, med tiden vil blive erstattet af circulær RNA.

[Boms]

@Buffet “Cutting-edge” er den opprinnelige beskrivelsen de brukte Her to utdrag fra presentasjonen i forbindelse med fusjonen med Oncos og børsnoteringen i juni 2015.

Selskapet er selvsagt noe helt annet nå, men mange skyr nok aksjen pga historikken og den generelle out-of-favour som gjelder for norsk biotech.

Håper selvsagt at de lykkes, men en ledelse som ikke skjønte hvor håpløs Atlas-avtalen var tar ikke jeg sjansen på å satse på at skal bygge aksjonærverdier.

[TekBot]

Atlas Holdings for CIRCIO

Pursuant to Securities Trading Regulation (STR), section 4-1, Atlas Special Opportunities, LLC hereby notifies you that we have crossed the notification requirement threshold in Circio Holding, with ticker CRNA, NO0013033795. Please see below for details on the ownership details resulting from transactions occurring on June 07, 2024. Please let us know if you require any additional information.

Value Date 06/07/2024
…

Vis børsmeldingen

Start of Day Position 1,681,638
End of Day Position 1,630,531
Outstanding Shares 10,654,822.00
Ownership Percentage 15.303%

Kilde

[TekBot]

Atlas Holdings for CIRCIO

To whom it may concern:

Pursuant to Securities Trading Regulation (STR), section 4-1, Atlas Special Opportunities, LLC hereby notifies you that we have crossed the notification requirement threshold in Circio Holding, with ticker CRNA, NO0013033795. Please see below for details on the ownership details resulting from transactions occurring on June 10, 2024. Please let us know if you require any additional information.
…

Vis børsmeldingen

Value Date 06/10/2024
Start of Day Position 1,630,531
End of Day Position 1,595,243
Outstanding Shares 10,654,822.00
Ownership Percentage 14.97%

Kilde

[TekBot]

Circio Holding ASA - Bridge financing requested from Atlas

Oslo, 13 June 2024: Reference is made to the stock exchange announcement by
Circio Holding ASA (OSE:CRNA) (“CIRCIO” or the “Company”) on 29 May 2024
regarding the terms and key information of the planned rights issue to raise
…

Vis børsmeldingen

gross proceeds of up to NOK 52 million (the “Rights Issue”), including the
commitment by Atlas Special Opportunities, LLC (“Atlas”) to provide the Company
with financing until completion of the Rights Issue by subscribing for bonds
with a nominal value of NOK 4 million (the “Bridge Financing”).

The Company has by a notice of exercise under the investment agreement entered
into with Atlas (the “Investment Agreement”), which was approved by an
extraordinary general meeting of the Company on 9 March 2023 and amended at an
extraordinary general meeting on 27 September 2023, formally called on the
Bridge Financing by requesting Atlas to subscribe and pay for eight convertible
bonds with an aggregate principal amount equal to NOK 4,000,000. Atlas will be
allocated these bonds under the terms and conditions of the Investment
Agreement.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA gene
therapies and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform for genetic
medicine. The proprietary circVec technology is based on a modular genetic
cassette design for efficient biogenesis of multifunctional circRNA from DNA and
viral vectors, which can be deployed in multiple disease settings. The circVec
platform has demonstrated enhanced and more durable protein expression than
classic mRNA vector systems, and has the potential to become the new gold
-standard for DNA and virus-based therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in three clinical trials: RAS-mutated
pancreatic cancer and lung and non-resectable pancreatic cancer in US, and
multiple myeloma in Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating read-outs and future
optionality for the program at low cost to Circio.

Kilde

[Boms]

Selskapet har tydeligvis knapt med cash, og låner derfor enda mer fra Atlas noe som svekker balansen deres. Så spørsmålet er jo nå om de har positiv egenkapital nå i perioden frem til emisjonen kommer på plass? Noen som har oversikt nok til å gjøre en kvalifisert gjetning??

[aol]

[aol]

Intervju med Erik fra i dag: ca. Fra 24 min.
https://www.redeye.se/events/1002957/investor-forum-online-29

[aol]

Norske Hanne presenterer EHA-studie med kreftvaksine fra norske Circio

[Xon]

Circio: Update on the circular RNA platform

[TekBot]

Circio announces strengthened in vivo data and enhanced circVec 2.2 design, presented by management in R&D webcast

· circVec 2.1 DNA vectors have now demonstrated higher and more durable
expression vs. conventional mRNA-based expression in vivo for up to five months
· Machine learning sequence optimization has resulted in a new and enhanced
…

Vis børsmeldingen

circVec 2.2 design, which increases protein expression by 2-4 -fold vs. circVec
2.1
· The enhanced circVec expression durability can deliver substantial
improvement over current gold-standard gene therapy approaches
· Circio management presents and discusses these data in a webcast published
today, 17 June 2024, watch the webcast here (https://redeye
-3.wistia.com/medias/bst2y63ily)

Oslo, Norway 17 June 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing next generation circular RNA vector technology for gene
therapy, today announces updated in vivo data. This new data demonstrates a
substantial durability advantage of Circio’s circVec technology over
conventional mRNA expression. In addition, Circio has undertaken sequence
optimization resulting in a new and enhanced circVec 2.2 design. The new data
are presented by Circio´s scientific leadership team in a
webcast (Circio 240613) released today 17 June
2024.

“The circVec 2.1 design is performing very well in vivo, and Circio has now
validated expression for up to five months. This is a clear demonstration of a
substantial, and statistically significant, advantage over mRNA-based
expression. As a result, the data provides an important proof-of-concept for
Circio´s circular RNA platform, which we expect will translate into improved
gene therapies for patients in the future,” said Dr. Thomas B Hansen, CTO at
Circio. “In parallel, we have deployed machine learning to optimize circVec
sequence composition. This has enabled us to generate a new and even more
powerful circVec 2.2 design, which increases protein expression by 2-4 -fold vs.
circVec 2.1 constructs.”

In parallel to the in vivo characterization, Circio has tested and incorporated
further features into the circVec platform. A dual-function ‘remove-&-replace’
concept has been designed and validated in vitro for Alpha-1-antitrypsin
deficiency (AATD). This concept has the ability to both replace functional AAT
protein and remove the disease variant. AATD is a genetic disease that causes
severe symptoms in the lung and liver. There are currently no satisfactory
therapeutic options available, and AATD represents a major unmet medical need
with over 200,000 patients affected in the USA and EU.

“In recent months, Circio has made important progress with its circVec AATD gene
therapy constructs. We have now technically validated a very efficient and
selective ‘remove’ functionality to complement the robust and durable circular
RNA ‘replace’ expression of the AAT protein,” said Dr. Victor Levitsky, CSO at
Circio. “Almost all gene therapies today are based on the AAV vector. We are
confident that circVec-based expression can enhance this format. Circio´s first
circular RNA AAV constructs have now been validated in vivo, and their
performance compared to conventional mRNA-AAVs will be tracked over the coming
months. We expect that these data will be of considerable interest to
prospective gene therapy partners.”

The new circVec data is presented and discussed by Circio´s CEO, CSO and CTO in
a webcast released today 17 June 2024 available via Circio´s webpage and the
Redeye platform.
Watch the webcast here (Circio 240613).

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA gene
therapies and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform for genetic
medicine. The proprietary circVec technology is based on a modular genetic
cassette design for efficient biogenesis of multifunctional circRNA from DNA and
viral vectors, which can be deployed in multiple disease settings. The circVec
platform has demonstrated enhanced and more durable protein expression than
classic mRNA vector systems, and has the potential to become the new gold
-standard for DNA and virus-based therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in three clinical trials: RAS-mutated
pancreatic cancer and lung and non-resectable pancreatic cancer in US, and
multiple myeloma in Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating read-outs and future
optionality for the program at low cost to Circio.

Kilde

[anon79663630]

https://register.epo.org/application?number=EP23821255

Confirmation of mRNA fears

[anon79663630]

@nordpolen

Man bruker ikke en gang vektorene.

Om det er egne vektorer du sikter til så gikk disse ned i sluket sammen med OY.

[anon79663630]

LG på vei til nye oppdrag, og på vei ut ?

https://swissrockets.com/team/extended-executive-management
https://torqur.com/team/extended-management
https://rocketvax.com/team/extended-management

Skal tro om noe av det som han evt realiserte av verdier i Timber ender i CRNA ? Er det ikke noe som heter “put your money where your mouth is” ?

(Timber Pharmaceuticals Announces Appointment of Dr. David Cohen and Dr. Lubor Gaal to Board of Directors)

https://www.timberpharma.com/team

https://www.globenewswire.com/news-release/2023/08/21/2728628/0/en/Timber-Pharmaceuticals-to-be-Acquired-by-LEO-Pharma.html

https://www.sec.gov/Archives/edgar/data/1504167/000143774923018258/tmbr20230622_8k.htm

Edit: Glem det som opprinnelig stod om LG`s eierskap i Timber. Her har jeg - som klippet over viser - gått fullstendig i baret. Dette handler om stemmer ifm valg av BOD. Må nok grave dypere for å finne ut hvor mye han evt har eid av aksjer. Om jeg orker.

[TekBot]

Flagging

Som følge av kapitalforhøyelsen i Circio Holding ASA («Selskapet») i forbindelse med konvertering av lån til aksjer i Selskapet, registrert 6. juni 2024 («Kapitalforhøyelsen»), har Høse AS falt under 5 %-terskelen for flagging av vesentlige aksjeposter. Etter Kapitalforhøyelsen innehar Høse AS 500 589 aksjer i Selskapet, tilsvarende ca. 4,7 % av Selskapets utestående aksjer og stemmer.

Denne flaggemeldingen er publisert i medhold av verdipapirhandelloven § 4-2, og er offentliggjort i henhold til § 5-12 i verdipapirhandelloven.
…

Vis børsmeldingen

Kilde